ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor.
Michels SYF, Scheel AH, Wündisch T, Heuckmann JM, Menon R, Puesken M, Kobe C, Pasternack H, Heydt C, Scheffler M, Fischer R, Schultheis AM, Merkelbach-Bruse S, Heukamp L, Büttner R, Wolf J.
Michels SYF, et al.
NPJ Precis Oncol. 2017 Mar 20;1(1):4. doi: 10.1038/s41698-017-0004-3. eCollection 2017.
NPJ Precis Oncol. 2017.
PMID: 29872693
Free PMC article.